Form 8-K - Current report:
SEC Accession No. 0001214659-24-017141
Filing Date
2024-10-03
Accepted
2024-10-03 16:30:12
Documents
17
Period of Report
2024-10-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 g1032408k.htm   iXBRL 8-K 27651
2 EXHIBIT 5.1 ex5_1.htm EX-5.1 7027
3 EXHIBIT 10.1 ex10_1.htm EX-10.1 190890
7 GRAPHIC olshanaddress_header.jpg GRAPHIC 10740
8 GRAPHIC olshanlogo_header.jpg GRAPHIC 7594
  Complete submission text file 0001214659-24-017141.txt   482232

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE alzn-20241003.xsd EX-101.SCH 2991
5 XBRL LABEL FILE alzn-20241003_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE alzn-20241003_pre.xml EX-101.PRE 22343
19 EXTRACTED XBRL INSTANCE DOCUMENT g1032408k_htm.xml XML 3914
Mailing Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326
Business Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

EIN.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-40483 | Film No.: 241351942
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)